Petros Grivas, MD
Immunotherapeutic developments in the advanced bladder cancer space have resulted in a number of ongoing combination trials with chemotherapy, targeted therapy, vaccines, and more that could shift the landscape once again.
OncLive: How has the management of advanced bladder cancer changed?
: We are living in a very exciting era with multiple advances in the field of advanced urothelial cancer. Over the last couple of years, we've had significant developments in understanding the molecular biology of advanced urothelial cancer. There have also been developments with immune checkpoint inhibitors. Now, we have 5 approved checkpoint inhibitors for patients with platinum-refractory advanced urothelial cancer. Two of them have been FDA approved for patients with a cisplatin-unfit phenotype.
... to read the full story